Propylthiouracil (PTU) - Uses

Propylthiouracil (PTU) is a thioamide antithyroid drug. It belongs to the same class as methimazole but has a distinct pharmacological profile that dictates its specific clinical niches.

Mechanism of Action

PTU works by two complementary mechanisms, which distinguishes it from methimazole:

Inhibits thyroid peroxidase - blocks iodine organification and coupling of iodotyrosines, thereby preventing new T3/T4 synthesis. This is shared with methimazole.
Inhibits peripheral deiodination of T4 to T3 - PTU blocks the conversion of T4 (the prohormone) to the more active T3 in peripheral tissues. Methimazole does NOT do this, making PTU uniquely useful when rapid reduction of T3 levels is needed.

Because PTU blocks synthesis rather than release of stored hormone, onset is slow - T4 stores take 3-4 weeks to deplete with routine dosing.

Katzung's Basic and Clinical Pharmacology, 16th Edition
Goodman & Gilman's The Pharmacological Basis of Therapeutics

Clinical Uses

1. Hyperthyroidism (Graves Disease and Other Causes)

PTU is used to treat thyrotoxicosis in three main ways:

Definitive therapy - to achieve euthyroidism while awaiting spontaneous remission in Graves disease, or as long-term management in patients who prefer medication over radioiodine or surgery
Pre-operative preparation - to render the patient euthyroid before thyroid surgery
Adjunct to radioactive iodine (RAI) - to hasten symptomatic recovery while awaiting the full effect of radiation

However, methimazole is the drug of choice for most adults and children due to its once-daily dosing, superior adherence, and lower hepatotoxicity risk. PTU carries a black-box warning for severe (sometimes fatal) hepatitis. Its use is therefore reserved for specific situations below.

Goodman & Gilman's The Pharmacological Basis of Therapeutics, p.971

2. First Trimester of Pregnancy (Preferred over Methimazole)

PTU is the drug of choice during the first trimester of pregnancy for women with hyperthyroidism (especially Graves disease). Reasons:

Methimazole is associated with methimazole-associated embryopathy (aplasia cutis, choanal atresia, tracheoesophageal fistula) in the first trimester
PTU is more strongly protein-bound and therefore crosses the placenta less readily than methimazole
After the first trimester, some experts recommend switching back to methimazole (which has lower maternal hepatotoxicity risk) since the critical organogenesis period has passed

Both drugs cross the placenta and can cause fetal hypothyroidism, so the lowest effective dose is used.

Harrison's Principles of Internal Medicine 22E, p.3945
Katzung's Basic and Clinical Pharmacology, 16th Edition

3. Thyroid Storm (Thyrotoxic Crisis)

PTU is a first-line agent in the treatment of thyroid storm, preferred over methimazole in this setting specifically because:

Its ability to block peripheral T4-to-T3 conversion provides a faster reduction in active thyroid hormone levels, which is critical in this life-threatening emergency
PTU is given in high loading doses (1000 mg PO x1, then 200 mg PO q6h is one common regimen)

Thyroid storm management is multimodal: PTU + iodine solution (given 1-2 hours AFTER PTU) + beta blockers (propranolol) + glucocorticoids + supportive care.

Fischer's Mastery of Surgery, 8th edition
Katzung's Basic and Clinical Pharmacology, 16th Edition

4. Alternative When Methimazole Causes Adverse Reactions

PTU may be used as an alternative when a patient develops adverse reactions to methimazole - except in cases of agranulocytosis or hepatitis from methimazole, as cross-sensitivity between the two drugs is approximately 50%.

Pharmacokinetics Summary

Parameter	PTU
Absorption	Rapid; peak at ~1 hour; bioavailability 50-80%
Plasma half-life	~75-90 minutes
Protein binding	High (more than methimazole)
Dosing frequency	Every 6-8 hours (q4-6h in high doses)
Excretion	Renal, as inactive glucuronide, within 24 hours

Despite the short half-life, PTU concentrates in the thyroid gland - a single 100 mg dose can inhibit organification by ~60% for 7+ hours.

Key Adverse Effects

Effect	Details
Fulminant hepatic necrosis	Rare but potentially fatal (~1:10,000 adults, 1:2,000 children) - black box warning
Agranulocytosis	0.1-0.5% incidence; usually in first 90 days; requires urgent discontinuation
Maculopapular rash	Most common adverse effect (4-6%)
ANCA-associated vasculitis	Long-term PTU use can induce MPO-ANCA seropositivity and rarely ANCA-associated glomerulonephritis
Nausea/GI distress	Common early
Lupus-like reaction, arthralgia	Rare

Katzung's Basic and Clinical Pharmacology, 16th Edition
National Kidney Foundation Primer on Kidney Diseases, 8e

Summary: When to Specifically Choose PTU

Clinical Situation	Rationale
First trimester of pregnancy	Lower placental transfer; avoids methimazole embryopathy
Thyroid storm	Blocks peripheral T4→T3 conversion (unique to PTU)
Methimazole intolerance	Alternative (avoid if cause was agranulocytosis/hepatitis)

For all other situations (non-pregnant adults, children, pre-surgical prep, long-term control), methimazole is preferred due to PTU's black-box hepatotoxicity warning.

Recent evidence note: A 2025 meta-analysis (PMID 40745151) and a 2026 network meta-analysis (PMID 41623375) continue to confirm the safety and efficacy profile of thioamides including PTU, with agranulocytosis risk being a dose-related concern relevant to both PTU and methimazole.

This is a shared conversation. Sign in to Orris to start your own chat.